Sinobiomed Inc.
OTC Bulletin Board : SOBM

Sinobiomed Inc.

May 14, 2008 09:01 ET

Phase II Clinical Trial of Sinobiomed's Malaria Candidate Vaccine to Start in Q3

Company Collaborating With Mahidol University of Bangkok on Trial to Be Conducted in Thailand

SHANGHAI, CHINA--(Marketwire - May 14, 2008) - Sinobiomed Inc. ("Sinobiomed", or the "Company") (OTCBB:SOBM) is pleased to announce that it is launching the Phase II Clinical Trial of its patented malaria vaccine candidate, PfCP2.9, in epidemic areas in Q3 2008.

Sinobiomed will conduct the trial in collaboration with Mahidol University in Bangkok, Thailand. The study site is located in Thailand's Ratchaburi Province, approximately 200 km from Bangkok near the Myanmar border. The university's Faculty of Tropical Medicine has extensive experiences in conducting vaccine trials. Since 1998, the faculty has participated in field trials for another malaria vaccine candidate in its Vaccine Trial Center (VTC) in Ratchaburi Province. Currently the VTC is sponsoring Phase II trials for an HIV vaccine and a dengue fever vaccine. Preparations for the Phase II trial of PfCP2.9 are now underway.

The Phase I Clinical Trial showed that PfCP2.9 had strong ability to generate an immune response (immunogenicity) with only mild adverse effects, and worked out the optimal dose levels and vaccination schedule required for the next trial. In January 2008, Sinobiomed was approved to receive grants from government funding of RMB 9 million (US$1.24 million) to undertake the Phase II clinical trial of its recombinant malaria vaccine in epidemic areas.

In 2004, Shanghai Wanxing received RMB 3 million (US $360,000) from the Ministry of Science and Technology to support the Phase I Clinical Trial of the vaccine. Sinobiomed has exclusive usage rights to the PfCP2.9 vaccine, which was developed by SMMU. PfCP2.9 has been granted Chinese, U.S., E.U. and Australian patents.


Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.

FORWARD LOOKING STATEMENTS: This news release may include "forward-looking
statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.

Contact Information